Lenz Therapeutics Shares Hit All-Time Low After 4Q Sales Underwhelm

Dow Jones03-24

By Connor Hart

Shares of Lenz Therapeutics fell to an all-time low after the company widened its fourth-quarter loss, as sales of its first commercial product got off to a slow start.

The stock was recently trading 13% lower, at $9.63, after hitting an all-time low of $9.21 shortly after Tuesday's opening bell. Shares have lost nearly two-thirds of their value over the past year.

The pharmaceutical company before the bell posted a comprehensive loss of $35.9 million for its three months ended Dec. 31, compared with a comprehensive loss of $13 million a year earlier.

The quarterly loss came out to $1.16 a share. Analysts polled by FactSet had expected a loss of 91 cents a share.

Revenue came in at $1.59 million, missing Wall Street models for $3.1 million. The top line consisted entirely of product sales of Vizz, an eye drop for the treatment of presbyopia, or the gradual loss with age of eyes' ability to focus on nearby objects.

The treatment received Food and Drug Administration approval in July, and the first commercial product sales began in October. Chief Executive Eef Schimmelpennink said Lenz remains focused on the commercialization of Vizz.

The company is working to accelerate adoption by expanding its sales force, driving focused field execution and sharpening physician messaging, he said. Lenz is also activating targeted consumer campaigns to establish Vizz as a compelling alternative to reading glasses, he added.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 24, 2026 10:31 ET (14:31 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621093003?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621093003","market":"fut","top_or_hot":-1,"title":"Lenz Therapeutics Shares Hit All-Time Low After 4Q Sales Underwhelm","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Lenz <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell to an all-time low after the company widened its fourth-quarter loss, as sales of its first commercial product got off to a slow start. \n</p>\n<p>\n  The stock was recently trading 13% lower, at $9.63, after hitting an all-time low of $9.21 shortly after Tuesday's opening bell. Shares have lost nearly two-thirds of their value over the past year. \n</p>\n<p>\n  The pharmaceutical company before the bell posted a comprehensive loss of $35.9 million for its three months ended Dec. 31, compared with a comprehensive loss of $13 million a year earlier. \n</p>\n<p>\n  The quarterly loss came out to $1.16 a share. Analysts polled by FactSet had expected a loss of 91 cents a share. \n</p>\n<p>\n  Revenue came in at $1.59 million, missing Wall Street models for $3.1 million. The top line consisted entirely of product sales of Vizz, an eye drop for the treatment of presbyopia, or the gradual loss with age of eyes' ability to focus on nearby objects. \n</p>\n<p>\n  The treatment received Food and Drug Administration approval in July, and the first commercial product sales began in October. Chief Executive Eef Schimmelpennink said Lenz remains focused on the commercialization of Vizz. \n</p>\n<p>\n  The company is working to accelerate adoption by expanding its sales force, driving focused field execution and sharpening physician messaging, he said. Lenz is also activating targeted consumer campaigns to establish Vizz as a compelling alternative to reading glasses, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 10:31 ET (14:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lenz Therapeutics Shares Hit All-Time Low After 4Q Sales Underwhelm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLenz Therapeutics Shares Hit All-Time Low After 4Q Sales Underwhelm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-24 22:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Lenz <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell to an all-time low after the company widened its fourth-quarter loss, as sales of its first commercial product got off to a slow start. \n</p>\n<p>\n  The stock was recently trading 13% lower, at $9.63, after hitting an all-time low of $9.21 shortly after Tuesday's opening bell. Shares have lost nearly two-thirds of their value over the past year. \n</p>\n<p>\n  The pharmaceutical company before the bell posted a comprehensive loss of $35.9 million for its three months ended Dec. 31, compared with a comprehensive loss of $13 million a year earlier. \n</p>\n<p>\n  The quarterly loss came out to $1.16 a share. Analysts polled by FactSet had expected a loss of 91 cents a share. \n</p>\n<p>\n  Revenue came in at $1.59 million, missing Wall Street models for $3.1 million. The top line consisted entirely of product sales of Vizz, an eye drop for the treatment of presbyopia, or the gradual loss with age of eyes' ability to focus on nearby objects. \n</p>\n<p>\n  The treatment received Food and Drug Administration approval in July, and the first commercial product sales began in October. Chief Executive Eef Schimmelpennink said Lenz remains focused on the commercialization of Vizz. \n</p>\n<p>\n  The company is working to accelerate adoption by expanding its sales force, driving focused field execution and sharpening physician messaging, he said. Lenz is also activating targeted consumer campaigns to establish Vizz as a compelling alternative to reading glasses, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 10:31 ET (14:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621093003","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621093003","pubTimestamp":1774362660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Lenz Therapeutics fell to an all-time low after the company widened its fourth-quarter loss, as sales of its first commercial product got off to a slow start.The stock was recently trading 13% lower, at $9.63, after hitting an all-time low of $9.21 shortly after Tuesday's opening bell. Shares have lost nearly two-thirds of their value over the past year.The pharmaceutical company before the bell posted a comprehensive loss of $35.9 million for its three months ended Dec. 31, compared with a comprehensive loss of $13 million a year earlier.The quarterly loss came out to $1.16 a share. Analysts polled by FactSet had expected a loss of 91 cents a share.Revenue came in at $1.59 million, missing Wall Street models for $3.1 million. The top line consisted entirely of product sales of Vizz, an eye drop for the treatment of presbyopia, or the gradual loss with age of eyes' ability to focus on nearby objects.The treatment received Food and Drug Administration approval in July, and the","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics"},"translate_title":"伦茨治疗公司(Lenz Therapeutics)第四季度销售表现不佳，股价跌至历史新低","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Lenz Therapeutics fell to an all-time low after the company widened its fourth-quarter loss, as sales of its first commercial product got off to a slow start. \n\n\n  The stock was recently trading 13% lower, at $9.63, after hitting an all-time low of $9.21 shortly after Tuesday's opening bell. Shares have lost nearly two-thirds of their value over the past year. \n\n\n  The pharmaceutical company before the bell posted a comprehensive loss of $35.9 million for its three months ended Dec. 31, compared with a comprehensive loss of $13 million a year earlier. \n\n\n  The quarterly loss came out to $1.16 a share. Analysts polled by FactSet had expected a loss of 91 cents a share. \n\n\n  Revenue came in at $1.59 million, missing Wall Street models for $3.1 million. The top line consisted entirely of product sales of Vizz, an eye drop for the treatment of presbyopia, or the gradual loss with age of eyes' ability to focus on nearby objects. \n\n\n  The treatment received Food and Drug Administration approval in July, and the first commercial product sales began in October. Chief Executive Eef Schimmelpennink said Lenz remains focused on the commercialization of Vizz. \n\n\n  The company is working to accelerate adoption by expanding its sales force, driving focused field execution and sharpening physician messaging, he said. Lenz is also activating targeted consumer campaigns to establish Vizz as a compelling alternative to reading glasses, he added. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 10:31 ET (14:31 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621093003","isCrawlerRequest":true}